These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 27480787)

  • 1. Implementation and Quality Control of Lung Cancer EGFR Genetic Testing by MALDI-TOF Mass Spectrometry in Taiwan Clinical Practice.
    Su KY; Kao JT; Ho BC; Chen HY; Chang GC; Ho CC; Yu SL
    Sci Rep; 2016 Aug; 6():30944. PubMed ID: 27480787
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prospective Validation of Rapid Plasma Genotyping for the Detection of EGFR and KRAS Mutations in Advanced Lung Cancer.
    Sacher AG; Paweletz C; Dahlberg SE; Alden RS; O'Connell A; Feeney N; Mach SL; Jänne PA; Oxnard GR
    JAMA Oncol; 2016 Aug; 2(8):1014-22. PubMed ID: 27055085
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Classification of Epidermal Growth Factor Receptor Gene Mutation Status Using Serum Proteomic Profiling Predicts Tumor Response in Patients with Stage IIIB or IV Non-Small-Cell Lung Cancer.
    Yang L; Tang C; Xu B; Wang W; Li J; Li X; Qin H; Gao H; He K; Song S; Liu X
    PLoS One; 2015; 10(6):e0128970. PubMed ID: 26047516
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Digital PCR analysis of plasma cell-free DNA for non-invasive detection of drug resistance mechanisms in EGFR mutant NSCLC: Correlation with paired tumor samples.
    Ishii H; Azuma K; Sakai K; Kawahara A; Yamada K; Tokito T; Okamoto I; Nishio K; Hoshino T
    Oncotarget; 2015 Oct; 6(31):30850-8. PubMed ID: 26334838
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pretreatment epidermal growth factor receptor (EGFR) T790M mutation predicts shorter EGFR tyrosine kinase inhibitor response duration in patients with non-small-cell lung cancer.
    Su KY; Chen HY; Li KC; Kuo ML; Yang JC; Chan WK; Ho BC; Chang GC; Shih JY; Yu SL; Yang PC
    J Clin Oncol; 2012 Feb; 30(4):433-40. PubMed ID: 22215752
    [TBL] [Abstract][Full Text] [Related]  

  • 6. EGFR T790M ctDNA testing platforms and their role as companion diagnostics: Correlation with clinical outcomes to EGFR-TKIs.
    Liang Z; Cheng Y; Chen Y; Hu Y; Liu WP; Lu Y; Wang J; Wang Y; Wu G; Ying JM; Zhang HL; Zhang XC; Wu YL
    Cancer Lett; 2017 Sep; 403():186-194. PubMed ID: 28642172
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Challenges to implementation of an epidermal growth factor receptor testing strategy for non-small-cell lung cancer in a publicly funded health care system.
    Ellis PM; Verma S; Sehdev S; Younus J; Leighl NB
    J Thorac Oncol; 2013 Sep; 8(9):1136-41. PubMed ID: 23887170
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Highly sensitive and noninvasive detection of epidermal growth factor receptor T790M mutation in non-small cell lung cancer.
    He C; Zheng L; Xu Y; Liu M; Li Y; Xu J
    Clin Chim Acta; 2013 Oct; 425():119-24. PubMed ID: 23886554
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Liquid biopsy for detection of EGFR T790M mutation in nonsmall cell lung cancer: An experience of proficiency testing in Taiwan.
    Ho HL; Huang CC; Ku WH; Ho CL; Lin CH; Yu SL; Chou TY
    J Chin Med Assoc; 2019 Jun; 82(6):473-476. PubMed ID: 30932938
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Rapid and Sensitive Method for Detection of the T790M Mutation of EGFR in Plasma DNA.
    Kimura H; Nishikawa S; Koba H; Yoneda T; Sone T; Kasahara K
    Adv Exp Med Biol; 2016; 924():171-174. PubMed ID: 27753039
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Highly Sensitive Droplet Digital PCR Method for Detection of EGFR-Activating Mutations in Plasma Cell-Free DNA from Patients with Advanced Non-Small Cell Lung Cancer.
    Zhu G; Ye X; Dong Z; Lu YC; Sun Y; Liu Y; McCormack R; Gu Y; Liu X
    J Mol Diagn; 2015 May; 17(3):265-72. PubMed ID: 25769900
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Longitudinal monitoring of EGFR mutations in plasma predicts outcomes of NSCLC patients treated with EGFR TKIs: Korean Lung Cancer Consortium (KLCC-12-02).
    Lee JY; Qing X; Xiumin W; Yali B; Chi S; Bak SH; Lee HY; Sun JM; Lee SH; Ahn JS; Cho EK; Kim DW; Kim HR; Min YJ; Jung SH; Park K; Mao M; Ahn MJ
    Oncotarget; 2016 Feb; 7(6):6984-93. PubMed ID: 26755650
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcomes of an Australian testing programme for epidermal growth factor receptor mutations in non-small cell lung cancer.
    Peters MJ; Bowden JJ; Carpenter P; Lewis J; Solomon B
    Intern Med J; 2014 Jun; 44(6):575-80. PubMed ID: 24720523
    [TBL] [Abstract][Full Text] [Related]  

  • 14. EGFR array: uses in the detection of plasma EGFR mutations in non-small cell lung cancer patients.
    Yam I; Lam DC; Chan K; Chung-Man Ho J; Ip M; Lam WK; Chan TK; Chan V
    J Thorac Oncol; 2012 Jul; 7(7):1131-40. PubMed ID: 22610259
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Highly sensitive detection of EGFR T790M mutation using colony hybridization predicts favorable prognosis of patients with lung cancer harboring activating EGFR mutation.
    Fujita Y; Suda K; Kimura H; Matsumoto K; Arao T; Nagai T; Saijo N; Yatabe Y; Mitsudomi T; Nishio K
    J Thorac Oncol; 2012 Nov; 7(11):1640-4. PubMed ID: 22899358
    [TBL] [Abstract][Full Text] [Related]  

  • 16. EGFR mutations in lung cancer: from tissue testing to liquid biopsy.
    Fenizia F; De Luca A; Pasquale R; Sacco A; Forgione L; Lambiase M; Iannaccone A; Chicchinelli N; Franco R; Rossi A; Morabito A; Rocco G; Piccirillo MC; Normanno N
    Future Oncol; 2015; 11(11):1611-23. PubMed ID: 26043215
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Variations in EGFR ctDNA Correlates to the Clinical Efficacy of Afatinib in Non Small Cell Lung Cancer with Acquired Resistance.
    He J; Tan W; Tang X; Ma J
    Pathol Oncol Res; 2017 Apr; 23(2):307-315. PubMed ID: 27511219
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TAE226, a Bis-Anilino Pyrimidine Compound, Inhibits the EGFR-Mutant Kinase Including T790M Mutant to Show Anti-Tumor Effect on EGFR-Mutant Non-Small Cell Lung Cancer Cells.
    Otani H; Yamamoto H; Takaoka M; Sakaguchi M; Soh J; Jida M; Ueno T; Kubo T; Asano H; Tsukuda K; Kiura K; Hatakeyama S; Kawahara E; Naomoto Y; Miyoshi S; Toyooka S
    PLoS One; 2015; 10(6):e0129838. PubMed ID: 26090892
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical likelihood of sporadic primary EGFR T790M mutation in EGFR-mutant lung cancer.
    Lee Y; Lee GK; Hwang JA; Yun T; Kim HT; Lee JS
    Clin Lung Cancer; 2015 Jan; 16(1):46-50. PubMed ID: 25450875
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predicting outcomes of EGFR-targeted therapy in non-small cell lung cancer patients using pleural effusions samples and peptide nucleic acid probe assay.
    Wang MC; Wang CL; Chen TL; Chang JW; Lu JJ; Chang PY; Chiou CC
    Clin Chem Lab Med; 2017 Oct; 55(12):1979-1986. PubMed ID: 28787267
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.